60.50
+10.00%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TaiMed Biologics
Its shares trade on Taipei Exchange under the ticker 4147.TWO. It has been listed since 28 June 2010. In the fiscal year to 31 December 2025, it reported revenue of TWD 611.4m and a net loss of TWD 167.8m. At that date it held total assets of TWD 4.81bn and shareholders' equity of TWD 3.86bn.
TaiMed Biologics, Inc. engages in the new drug development for human immunodeficiency virus (HIV). The company is headquartered in Taipei City, Taipei. The company went IPO on 2010-06-28. The firm mainly provides ibalizumab (TMB-355) and TMB-360, which are applied in the treatment of acquired immune deficiency syndrome (AIDS), and protease inhibitor (TMB-607), which is applied as pro-drugs for AIDS. The firm's ibalizumab is a humanized monoclonal antibody, which can interfere with the penetration of the virus into the cell. Its protease inhibitor uses nanotechnology formulation for subcutaneous and/or intramuscular injections.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Jun 2010
- Employees
- 12
- Website
- taimedbiologics.com ↗
Leadership
Pay as last reported
- Ming-Tsuen ChenChairman of the Board, since 2025
- Mr. Chin-Ming ChangChief Executive Officer, General Manager, Director, since 2018TWD 15.5m
- Mr. Jack ChenChief Financial OfficerTWD 6.1m
- Iven HoHead of Accounting, Corporate Governance Officer
- Kenny LinHead of Finance
- Mr. Chi-Chuan ChenDirector, since 2008
- Ms. C.C ChengDirector
- Mr. Shih-Chia LinDirectorTWD 212,000
- Mr. Ta-Mon TsengDirector
- Mr. Chin-Ting ChiuIndependent DirectorTWD 1.1m
- Mr. Howard S. LeeIndependent DirectorTWD 1.1m
- Mr. Gwo-Fong LinIndependent DirectorTWD 1.1m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 66
- Social
- 99
- Governance
- 51
- Direct emissions (scope 1)
- 620.055 t
- Energy emissions (scope 2)
- 1,992.487 t
- Value chain emissions (scope 3)
- 531.151 t
- Women in the workforce
- 57%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company focuses on HIV and AIDS drug development with products like ibalizumab and protease inhibitors.
- Products include TMB-355, TMB-360, and TMB-607 for AIDS treatment.
- Company has a small team of 12 employees.
Weaknesses
- Company has only 12 employees, indicating limited workforce capacity.
- Products are focused on HIV and AIDS, which may limit market diversification.
- Company is headquartered in Taipei City, which may restrict global market access.
Opportunities
- Potential for expanding HIV and AIDS treatment market with new drug developments.
- Nanotechnology formulation for protease inhibitor could offer competitive advantages.
- IPO in 2010 provides a foundation for future growth and investment.
Threats
- Dependence on HIV and AIDS treatments may pose risks if market demand changes.
- Small employee count may hinder rapid response to market changes.
- Headquarters in Taipei City could face geopolitical or regulatory challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.